SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Lab and Daiichi Sankyo to launch Olmesartan medoxomil

02 Aug 2011 Evaluate

Ranbaxy Laboratories and Daiichi Sankyo Company have agreed to expand the group’s business in Mexico with the launch of Olmesartan medoxomil. The product is expected to be introduced in the market before the end of 2011.

Daiichi Sankyo Mexico  S.A de C.V (DSMX), newly established  subsidiary of Daiichi Sankyo, and Ranbaxy Mexico  S.A de C.V (RMEX) subsidiary of Ranbaxy will leverage the group’s hybrid business model in Mexico by utilizing the business know how  and cost advantage of Ranbaxy, thereby offering both innovative and affordable, high quality generic medicines.

Olmesartan medoxomil is a member of the angiontensin receptor blocker (ARB) class of antihypertensive medications that helps lower blood pressure by blocking the agniotensin II receptor on the blood vessels and antagonizing the release of the hormone which causes salt retention and increased blood volume.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×